Biogen Idec pioneered the development of novel products based on advances in molecular biology and recombinant DNA, and markets two of the biotechnology industry’s first blockbuster medicines, AVONEX^® (interferon beta-1a) and RITUXAN^® (rituximab). With TYSABRI^® (natalizumab) we developed a breakthrough therapy for the treatment of multiple sclerosis (MS).

Our commitment to improving the lives of patients guides our every action. We are enthusiastic and entrepreneurial, spurred by our quest for innovation and led by our ethical standards in business conduct. We are one of the few biotechnology companies with a global presence. Our international business began in 1995 and today we operate in 29 countries with distribution partners in over 70.

As a global leader in the discovery, development, manufacturing and commercialization of novel therapies, we at Biogen Idec are dedicated to delivering results for our patients, the healthcare community, our employees and shareholders.